866-997-4948(US-Canada Toll Free)

Apidra (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 44 Pages


GlobalDatas pharmaceuticals report, Apidra (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Apidra sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.


Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Apidra including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Apidra including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Apidra in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 20

6.1 Insulin 20
6.2 Oral Medications 20
6.2.1 Sulfonylureas (SUR) 20
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 22
6.2.4 Meglitinides 22
6.2.5 Thiazolidinediones (TZDs) 23
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 24
6.2.7 Oral Combination Therapy 24
6.3 Other Injectionable Medications 25
6.3.1 Pramlintide 25
6.3.2 Exenatide 25
6.4 Market Share as per Classes in Type 2 Diabetes 25

7 Apidra (insulin glulisine) 26
7.1 Introduction 26
7.2 Mechanism of Action 26
7.3 Clinical Studies 26
7.3.1 Type 2 Diabetes-Adult 26
7.4 Approval History of Apidra 27
7.5 Factors Affecting Sales of Apidra 27
7.5.1 Growing Insulin Market 27
7.5.2 Advantage of Apidra over Regular Human Insulin 27
7.5.3 Prevention of Spiking Blood Sugar between Meals 27
7.5.4 Effective Treatment for Low Blood Sugar at Night 27
7.5.5 Late Entry of Apidra as Compared to Other Rapid Acting Insulin Analogs 28
7.6 Drug Evaluation 28
7.6.1 Drug Risk Benefit Score 28
7.6.2 Intensity of Competition 29
7.7 Sales Estimates 30
7.7.1 Target Patient Pool for Apidra 30
7.7.2 Dosing 30
7.7.3 Market Penetration 30
7.7.4 Annual Cost of Therapy 30
7.7.5 Sales Projections of Apidra 31

8 Diabetes Market: Appendix 40
8.1 Market Definitions 40
8.2 List of Abberiviations 40
8.3 Research Methodology 40
8.3.1 Coverage 41
8.3.2 Secondary Research 41
8.3.3 Forecasting 41
8.3.4 Net Penetration of Drug 42
8.3.5 Net Annual Dosing 42
8.3.6 Annual Cost of Therapy 42
8.3.7 Primary Research 42
8.3.8 Expert Panels 42
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 43
8.7 Sources 44

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 19
Table 9: Comparison of Means of Glycemic Parameters at the end of Combined Treatment periods 26
Table 10: Approval of Apidra 27
Table 11: Drug Risk Benefit Score of Apidra 28
Table 12: Adverse events in patients with type 2 diabetes 28
Table 13: Apidra, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 30
Table 14: Apidra, Type 2 Diabetes, Global, Sales Estimates ($m), 20042020 31
Table 15: Apidra, Type 2 Diabetes, The US, Sales Estimates ($m), 20062020 32
Table 16: Apidra, Type 2 Diabetes, The UK, Sales Estimates ($m), 20052020 33
Table 17: Apidra, Type 2 Diabetes, France, Sales Estimates ($m), 20052020 34
Table 18: Apidra, Type 2 Diabetes, Germany, Sales Estimates ($m), 20042020 35
Table 19: Apidra, Type 2 Diabetes, Italy, Sales Estimates ($m), 20052020 36
Table 20: Apidra, Type 2 Diabetes, Spain, Sales Estimates ($m), 20052020 37
Table 21: Apidra, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20092020 38

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylurea 20
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 21
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 22
Figure 9: Mechanism of Action of Thiazolidinediones 23
Figure 10: Mechanism of Action of DPP IV Inhibitors 24
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 25
Figure 12: Apidra, Type 2 Diabetes, Global, Sales Estimates ($m), 2004-2020 31
Figure 13: Apidra, Type 2 Diabetes, The US, Sales Estimates ($m), 20062020 32
Figure 14: Apidra, Type 2 Diabetes, The UK, Sales Estimates ($m), 20052020 33
Figure 15: Apidra, Type 2 Diabetes, France, Sales Estimates ($m), 20052020 34
Figure 16: Apidra, Type 2 Diabetes, Germany, Sales Estimates ($m), 20042020 35
Figure 17: Apidra, Type 2 Diabetes, Italy, Sales Estimates ($m), 20052020 36
Figure 18:Apidra, Type 2 Diabetes, Spain, Sales Estimates ($m), 20052020 37
Figure 19: Apidra, Type 2 Diabetes, Japan, Sales Estimates ($m), 2009-2020 38
Figure 20: Apidra, Type 2 Diabetes, Sales Distribution by Country (%), 2020 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *